During the past decade, antisense oligonucleotides (ONs) have gained attention as a possible human immunodeficiency virus type 1 (HIV-1) inhibitor (41) . Most antisense studies against HIV-1 have been performed using chemically modified ONs, including phosphorothioate (PAS) ONs (9-11, 16, 21-23, 26, 29-31, 36, 42, 47, 48, 50, 51, 53) , methylphosphonate ONs (15, 32, 46) , or phosphoramidates ONs (6, 12, 14) , in order to improve the stability of the antisense ONs against nucleases. Among these modified ONs, PAS ONs have been studied most extensively due to a host of beneficial properties: strong nuclease resistance (10, 11) , higher solubility (26) , and relatively intense anti-HIV-1 activity (9, 16, 21-23, 29-31, 36, 42, 47, 48, 50, 51, 53) . Nevertheless, the PAS ONs are also associated with some disadvantages, including their propensity for interaction with membrane proteins via a specific mode of action (8, 25, 45) , as well as the fact that higher concentrations of these ONs are required than of the existing antiviral drugs.
Several studies have been performed to explain the possible mechanisms underlying the anti-HIV-1 activity of each PAS ON. The mechanisms suggested have included adsorption blocking (9, 16, 47, 50, 51, 53) and inhibition of HIV-1-specific enzymes, such as reverse transcriptase (29) (30) (31) or integrase (21-23, 36, 42) . However, most studies of the antiviral mechanisms of PAS ONs, as well as recent studies with small interfering RNA (siRNA) against HIV-1 (3, 5, 7, 35, 38, 39, 49) , have been conducted by transfection or viral vector-mediated delivery (4, 17, 27, 33, 34) , rather than simple treatment of the infected culture. Those transfection steps may impede, to some extent, the application of antisense or siRNA under physiological conditions.
We reported previously that the PAO ONs containing modified adenosine (A), with a six-membered azasugar (6-AZS) instead of a five-membered ribose at the sugar moiety of A, facilitated formation of stable duplexes with mRNA, depending on the location and number of the substitutions (20, 24) . In the present study, we synthesized six-membered azasugar nucleotide (6-AZN)-containing PAS oligonucleotides (AZPSONs), designed in specific sequences which are complementary to the HIV-1 RNA genome, primarily to the trans-activation response (TAR) region of the HIV-1 long terminal repeats (LTR), or in random sequences. We then assessed the anti-HIV abilities of these AZPSONs. While the PAS ON itself exhibited little if any anti-HIV-1 activity, most of the AZPSONs exhibited potent anti-HIV-1 activity without the aid of any transfecting agents and were also found to be very stable against enzymatic degradation.
Among the AZPSONs, DBM 2198, containing five 6-AZNs in a random sequence, was found to be the most potent for its anti-HIV-1 activity against T-cell-tropic, monotropic, and drug-resistant HIV-1 variants. The treatment of infected cultures with DBM 2198 did not cause any cytotoxicity to the host cells. The mechanisms underlying the anti-HIV-1 properties of DBM 2198 have been examined through a series of experiments, including sequence-specific LTR promoter inhibition assays, calcium mobilization assays, infection inhibition assays, and flow cytometry analysis (manuscript submitted). In the present manuscript, we report first the azasugar-containing PAS ONs and AZPSONs and their remarkable activities against a broad spectrum of HIV-1 variants.
MATERIALS AND METHODS
Synthesis of AZPSONs and other ONs. The synthesis of modified adenine nucleoside (6-AZN) containing 6-AZS has been previously reported (24) . In the present experiments, we synthesized AZPSONs and other ONs with 6-AZN, using an automated DNA synthesizer (Applied Biosystems 392, Foster, CA) based on standard chemistry at a 1-mole scale. In order to incorporate a modified nucleotide, we employed a coupling time of 600 seconds. The PAS ONs were prepared using tetraethylthiuram disulfide (TETD). The yield of the modified PAS ONs coupling was 90 to 98%, and all ONs were purified by reverse-phase HPLC with an acetonitrile gradient (18 to 48%) in a 100 mM triethylammonium actetate buffer (pH 7.0). Polyacrylamide gel electrophoresis (PAGE) was used to confirm the purity of the ONs.
Cells and viruses. Jurkat-tat (Tat-expressing Jurkat cells) cells were obtained from J. Sodroski (Dana-Farber Cancer Institute, Harvard Medical School). MT-4, C8166, CEMX-174, HeLa-CD4-LTR-␤-gal (Magi) cells, U373-CD4-CXCR4-Magi, and U373-CD4-CCR5-Magi cells were obtained from the AIDS Research and Reference Reagent Program (National Institutes of Health). Jurkat E6 (TIB152), HeLa cells (CCL2), and Vero cells were purchased from the American Type Culture Collection. Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy donors, using Ficoll-Hypaque (Sigma Chem. Co.) density gradient centrifugation, as was described previously (36) , and were also used in our experiments. HXBc2 and HXBc2/⌬tat (tat-defective HIV-1 laboratory strain) were kindly provided by J. Sodroski (DFCI, Harvard Medical School). HIV-1 IIIB , HIV-1 MN , HIV-1 CC , HIV-1 RTMDRI (virus resistant nevirapine, zidovudine, and dideoxyinosine), HIV-1 Saquinavir-R , HIV-1 Ada-M , HIV-1 Ba-L , and SHIV 89.6 were all obtained from the AIDS Research and Reference Reagent Program.
Antiviral activity assay. Jurkat-tat or C8166 cells were infected with different HIV-1 strains at an appropriate multiplicity of infection (MOI; 0.001 to 0.2 depending on the experiment) for 1 h at 37°C, then cultured in media containing different concentrations of AZPSONs and other ONs together with dextran sulfate as a reference compound. The antiviral activity of each AZPSON was assessed according to the inhibition of HIV-1 replication, which was measured by the amount of syncytia and/or reverse transcriptase (RT) activity, or by a visual infection assay (52) . The antiviral activity of each DBM ON was also expressed by the concentration required for the inhibition of 50% of virus-mediated cell killing, in comparison with an untreated control (EC 50 ). Cells were infected with a 0.01 multiplicity of infection (MOI) of several different HIV-1 strains, then cultured in the presence of serially diluted DBM ONs. The EC 50 values were calculated 4 days postinfection by a tetrazolium-based MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] (Sigma Chemical Co.) assay, as previously described (37) .
Reverse transcriptase assay. Virion-associated RT activity was evaluated as follows: Two-thirds of the culture fraction containing the HIV-1 infected cells was harvested every 3 days, disrupted by vigorous vortexing, then clarified by a quick centrifugation at 15,000 rpm for 15 seconds. The supernatants were then mixed with equal volumes of polyethylene glycol/NaCl solution (30% polyethylene glycol in 0.4 M NaCl), mixed thoroughly, and incubated for 12 h at 4°C. After 45 min of centrifugation at 15,000 rpm, the pellets were resuspended with 10 l of dissociation buffer (0.25% triton X-100, 20% glycerol, 50 mM Tris-HCl, pH 7.5, 0.1% dithiothreitol, and 250 mM KCl) and then examined for RT activity, as previously described (44) .
Visual infection assay for titration of infectious virion. A visual infection assay was performed as described previously (37) , with some minor modifications. In brief, monolayers of U373-CD4-CXCR4-Magi, or U373-CD4-CCR5-Magi cells were infected with serially diluted HIV-1 solutions for 1 h, washed twice with phosphate-buffered saline, then cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc.), supplemented with 10% fetal bovine serum. Two days after initial infection, the cells were washed and fixed with 1% formaldehyde and 0.2% glutaraldehyde solution, then stained with 0.04% 5-bromo-4-chloro-3-indoryl-␤-D-galactopyranoside (X-Gal; Molecular Probes, Eugene, OR) for 2 h at 37°C. Blue cells were counted under an inverted microscope, and expressed as the titer of infectious virus particles in each sample.
Cell cytotoxicity. The cytotoxicity of the DBM ONs was assessed using MT-4, Jurkat, C8166, Vero, CEMx-174, U937, and HeLa cells. Cells in 96-well plates (2 ϫ 10 4 cells/well) were incubated with serially diluted DBM ONs for 4 days, and the number of viable cells was quantified via MTT assays. Cytotoxicity was assessed according to the concentration of ONs required to reduce cell viability by 50% (CC 50 ).
Statistical analysis. Most statistical data were recorded in triplicate, and results were expressed as geometric means Ϯ standard deviation. Statistical significance was evaluated by Student's t tests. Data with a P value of Յ0.01 were considered significant.
RESULTS
AZPSONs exhibit potent anti-HIV-1 activity. Figure 1 shows the structure of the AZN-containing PAS ONs. Table 1 lists the sequences of the modified and unmodified ONs and exhibits the anti-HIV-1 activity of each ON. The ONs targeting the partial sequences of HIV-1 TAR, upstream LTR, LTR splicing donor site, gag, SIV TAR and poliovirus internal ribosome entry site (IRES) (2), together with random-sequence 18-to 22-mer ONs and a few G-quartet analogue ONs were synthesized with PAS, PAO, or mixed (PAS and PAO) backbones.
These ONs were evaluated for their anti-HIV activity according to their ability to inhibit syncytium formation when treated to the culture of HIV-1 (HXBc2/⌬tat)-infected Jurkattat cells. The anti-HIV-1 activities exhibited by the DBM ONs (AZPSONs and other ONs) were summarized (Table 1) . DBM 2133, 2134, 2193, 2194, 2195 (antisense to TAR), 2177 (antisenses to HIV LTR), and 2196, 2197, 2198, 2199, and 2240 (random sequence) induced the significant inhibition of HIV-1-mediated syncytium formation, after a single treatment of the infected culture at a final concentration of 0.1 M. In particular, DBM 2193, 2196 and 2198 appeared to be much more effective than zidovudine in terms of their long-term term antiviral activities after a single treatment. Neither the 6-AZN monomer (DBM 2182), nor its monophosphate form, exhibited antiviral activity, leading us to dismiss the possibility that the antiviral activity of these AZPSONs might be attributable to the AZN monomer itself, or to a decomposition intermediate of AZN. DBM 2136, however, which harbors no AZN in its PAS linkages, induced rapid and serious syncytium formation, rather than inhibition. The PAO linkage (DBM 2137) or mixed backbone (PAS and PAO) ONs (DBM 2237 to 2239), exhibited unremarkable antiviral activity, although they did harbor 6-AZNs.
The G-quartet ONs were reported to be effective anti-HIV compounds, and some of them had been subjected to preclinical studies (1, 40) . We introduced the 6-AZN to the G quartet PAS ON, synthesizing DBM 2200. DBM 2201 contains a dimethoxytrityl group on the 5Ј-end of the modified G-quadruplex in its PAO linkage, which was synthesized as described in previous reports (13, 16, 53) . However, neither of these exhibited any significant anti-HIV-1 activity (Table 1) . We also evaluated the abilities of another set of G-quartet ONs (DBM 2244 and 2245), which contained the same sequences as did ISIS-5320 (9, 53) and T30177 (Zintevir) (23, 36) , together with AZPSONs. Our results indicated that many AZPSONs (DBM 2134, 2193, 2194, 2196, 2198 and 2240) exhibited much more potent anti-HIV activity than did the G-quartet ONs, at least with regard to long-lasting efficacy after a single treatment at a concentration of 0.1 M (Table 1) .
Dose-dependent inhibitory effects of AZPSONs on HIV-1 replication. In order to determine whether AZPSONs' antiviral activity shown in Table 1 was specific to the suppression of HIV-1 replication or to the nonspecific side effects, we evaluated the anti-HIV activity of five remarkable AZPSONs and control PAS ONs (DBM 2136), at several different concentrations. As shown in Fig. 2 , the selected AZPSONs (DBM 2134, 2177, 2193, 2198, and 2140) resulted in the inhibition of syncytium formation, in a dose-dependent manner. It implies that the antiviral activity of AZPSONs was not attributable to a side effect. Most of them exhibited strong antiviral activity at concentrations greater than 0.06 M. DBM 2136 exhibited no inhibitory effects on HIV-1 replication; rather, it appeared to enhance viral replication. The effects of DBM 2136 were reexamined, and discussed in the next section.
Serum effects on the antiviral activity of AZPSONs. PAS ONs have been reported to bind plasma proteins, such as albumin (53) . To see whether serum proteins would also attenuate the antiviral activity of AZPSONs, DBM 2134 and 2198 were examined in a serum-containing RPMI medium (RPMI 10 ). As shown in Fig. 3 , while DBM 2134 was markedly attenuated in its antiviral activity in the presence of serum, compared with that in serum-free medium that of DBM 2198 was minimally attenuated by serum at a final concentration of 0.1 M (Fig. 3A) . Nevertheless, these AZPSONs (DBM 2134 and 2198) still showed complete inhibition of HIV-1 replication at a final concentration of 0.5 M, even in the presence of serum (Fig. 3B) . Serum effects on the other AZPSONs (DBM 2193, 2196, and 2240) were similar to those of DBM 2134 or DBM 2198, respectively (data not shown). The kinds of sera (fetal bovine, human, and horse serum) and concentrations of sera (5%, 10%, and 50% of fetal bovine serum) did not cause any additional attenuation of the antiviral activity of the AZPSONs (data not shown), suggesting that effective AZPSONs, such as DBM 2198, can be used as anti-HIV-1 drugs in physiological conditions. EC 50 of AZPSONs. The EC 50 values of the selected AZPSONs, together with zidovudine, dideoxycytosine, and dideoxyinosine, and dextrans sulfate, a well-documented fusion inhibitor, were determined using three different HIV-1 variants and susceptible host cells, as described in the Materials and Methods section, and summarized in Table 2 . The treatment of infected cells with AZPSONs (DBM 2134, 2193, 2196, 2198, and 2240) inhibited the replication of all three HIV-1 variants, with EC 50 s ranging from 0.05 to 0.23 M ( Table 2 ). The AZPSONs were much more effective against HIV-1 IIIB than were dideoxycytosine or dideoxyinosine, but were not as effective as zidovudine on a molar scale. Notably, the AZPSONs also proved to be very effective against the SIV-HIV chimeric recombinant virus SHIV 89.6 , which exhibits resistance to zidovudine even at an extreme concentration (400 M). Among the AZPSONs, DBM 2198 proved to be the most effective against these T-cell-tropic and monotropic HIV-1 variants (0.05 Ͻ EC 50 Ͻ 0.10 M), while 2 to 10 M of DBM 2136 (no AZN in the PAS ON backbone) was required for a 50% inhibition of HIV-1 replication (EC 50 ). dextran sulfate was very efficient in inhibiting the T-cell-tropic HIV-1 variants, but was not effective at all in the inhibition of the monotropic Ba-L strain, as described previously (18, 19) .
Cell cytotoxicity and therapeutic indices of AZPSONs. The cytotoxicity of each AZPSON was determined by means of MTT assays, and the CC 50 s of the AZPSONs are summarized in Table 3 . While PAS ON without AZN (DBM 2136) showed relatively lower CC 50 s (Ͻ100 M) in four out of six cell types, most of the AZPSONs exhibited CC 50 s over 100 M in more than half of the tested cell lines, suggesting that the AZN would attenuate the toxicity of the PAS ONs.
The therapeutic indices (TI ϭ CC 50 /EC 50 ) of the tested AZPSONs were at least higher than 400 (TI of DBM 2134: CC 50 ϭ 67 M and EC 50 ϭ 0.16 M for SHIV 89.6 in C8166). Whereas, the most effective AZPSON, DBM 2198, proved to have TI scores higher than 2,000 for HXBc2/⌬tat in Jurkat-tat cells, 1250 for HIV-1 IIIB in MT-4 cells, and 1,000 for HIV-1cc and SHIV 89.6 in C8166 cells. These data strongly suggest that the AZPSONs are very safe and effective for the inhibition of HIV-1 replication.
DBM 2198 inhibits a broad-spectrum of HIV-1 variants. DBM 2198 was the most potent among the tested APZONs with regard to anti-HIV-1 activity against a laboratory strain (HIV-1 IIIB ), a recombinant virus (HXBc2/⌬tat), and the chimeric recombinant SHIV 89.6 , as illustrated in Table 2 . In the next phase of our study, we attempted to determine whether DBM 2198 exhibits similar anti-HIV-1 activity when encountering other HIV-1 variants. As shown in Fig. 4A , all six T-celltropic variants were inhibited by over 95% as the result of a single treatment of DBM 2198, at a final concentration of 0.5 M. Interestingly, the drug-resistant HIV-1 variants (Saquinavir-resistant and zidovudine, dideoxyinosine, nevirapine-resistant) were found to be much more susceptible to DBM 2198-induced inhibition than were the primary isolates or recombinants (Fig. 4A) . DBM 2198's potent anti-HIV effects were also observed in trials with monotropic virus-infected cells. As shown in Fig. 4B , the number of infected cells (in the visual infection assay) was markedly reduced, in a dose-dependent manner, when U373-CD4-CCR5-Magi cells were infected with 0.01 MOI of monotropic HIV-1 variants (Ada-M and Ba-L), in the presence of DBM 2198. These results clearly suggest that DBM 2198 works against a broad spectrum of HIV-1 variants, including drug-resistant HIV-1 strains. 
DBM 2198 works against acute HIV-1 infection.
In order to determine whether DBM 2198 remains effective acute HIV-1 infection, we assessed the antiviral activity of DBM 2198 in cultures infected with a high MOI of HIV-1 IIIB , as described previously (42) . HIV-1 replication was observed to be minimal or undetectable when the cells were infected with 0.05 MOI or lower in the presence of DBM 2198. However, the HIV-1 titers were scored at about 15% and 30% of that of the 2198-untreated controls when infected with 0.1 and 0.2 MOI, respectively, at a concentration of 0.5 M DBM 2198 (Fig. 5A) . This indicates that once the cells were infected with the virus, DBM 2198 could not impede the first round of HIV-1 replication, which was followed by the production of progeny viruses in proportion to the initial MOI. However, further propagation did appear to be inhibited by DBM 2198-mediated blocking of the second infection, resulting in a very much lower titer of virus in the culture, compared with that of the untreated controls.
To see whether DBM 2198 was also effective for blocking HIV-1 spread in severely infected cultures, Jurkat-tat cells exhibiting strong syncytium formation were treated with DBM 2198 at a final concentration of 0.5 M, and then monitored for 2 days. In repeated experiments, most of the syncytia in the DBM 2198-treated disappeared within 2 days (Fig. 5B) . Possible mechanisms are suggested in the Discussion section. On the contrary, DBM 2136 (PAS ON) exacerbated, rather than inhibited, the rate and severity of syncytium formation (Fig.  5B) , which is consistent with our results shown above (Table 1 , Fig. 2 and Fig. 3) .
DBM 2198 maintains its potency in the inhibition of HIV-1 replication in PBMC. DBM 2198 proved effective, blocking HIV-1 replication in PBMCs regardless of the host tropisms (Fig. 6 ). T-cell-tropic viruses in the infected PBMC cultures were dramatically inhibited by DBM 2198 treatment, while DBM 2241 (the same sequence as DBM 2198 but harboring no AZN) proved ineffective in the inhibition of these viruses (Fig.  6A ). This indicates that the AZNs in DBM 2198 are essential for the inhibition of T-cell-tropic viruses. However, DBM 2241 exhibited remarkable, although incomplete, inhibitory effects on the monotropic Ba-L strain, as shown in the cultures treated with DBM 2198 (Fig. 6B) .
DISCUSSION
In this study, we demonstrated that newly designed 6-membered Azasugar-containing PAS ONs (AZPSONs) exhibit potent antiviral activity against HIV-1 infection. These anti-HIV-1 properties of AZPSONs require only a simple administration into an infected culture without any extra transfection processes. The substitution of sugar moieties with six-membered azasugars (6-AZS) in PAS ONs appear to be an essential factor in the potent anti-HIV-1 properties of the AZPSONs, as little, if any antiviral activity was exhibited by PAS ONs such as DBM 2136 or DBM 2241 alone, although they carry nucleotide sequences identical to those of the AZPSONs DBM 2134 and DBM 2198, respectively (Table 1, Fig. 2 ). The PAS ONs themselves have been studied extensively, due to their remarkable anti-HIV-1 properties. In the present study, however, the PAS ON itself was not as effective as was previously reported when administered in cultures without transfection. Whereas AZPSONs containing specific substitutions of the sugar moiety of adenosine in their PAS ONs proved to exert much more potent anti-HIV-1 effects than did the PAS ONs alone (Table  1) . Nevertheless, the PAO backbone only exhibited no intrinsic anti-HIV-1 activity, nor did the mixed backbone (PAO and PAS) oligonucleotides, even though those ONs contained 6-AZNs. These results indicate that the PAS backbone and the 6-AZS substitutions of sugar moiety are both essential to the anti-HIV-1 properties of the AZPSONs. The anti-HIV-1 capacity of the AZPSONs seems to depend on the number and/or distribution patterns of the 6-AZN in the ONs. The DBM 2193 containing four AZNs was better than three AZN-containing DBM 2134 in its anti-HIV-1 activity, even though both of them have the same nucleotide sequence. DBM 2198, the most effective among the AZPSONs, has a random sequence and five 6-AZNs evenly distributed in 18 nucleotides. However, six (DBM 2194, anti-TAR) or seven (DBM 2199, random) AZN-containing ONs were not as effective as DBM 2193 (three AZNs, anti-TAR) or DBM 2198 (five AZNs, random), respectively, suggesting that the number of AZNs is not the sole factor for the anti-HIV-1 activity of AZPSONs. DBM 2197 and 2198, containing the same number of AZNs, but having four and three nucleotides between the AZNs, respectively, exhibited different antiviral activities. In addition, both DBM 2198 and 2240, which have the same number of AZNs (five AZNs) and spacer nucleotides but with different compositions of spacer nucleotides (CTC and CGC, respectively), showed different antiviral activities. DBM 2192 (9-mer) and 2181 (18-mer), having identical AZN composition, showed similar anti-HIV-1 activity, even though DBM 2198 has an extra nine PAS ON. These results suggest that the distribution patterns of the AZNs and the composition of the spacer nucleotides between the AZNs influence the antiviral activity of the AZPSONs. The length of the PAS backbone itself, however, may not play a crucial role in the antiviral activity of AZPSONs.
As shown in Fig. 2 , AZPSONs inhibited the syncytium formation in a dose-dependent manner, but the dose-dependent responses of each AZPSON did not exhibit a clear linearity. We are not sure whether these dose-dependent response patterns are special characteristics of AZPSONs or not, but the results from our repeated experiments lead us to assume that each AZPSON has its own threshold concentration for the phenotypic inhibition of HIV-1 replication.
Among the AZPSONs, DBM 2198 was clearly the most effective with regard to its antiviral activity against, not only T-cell-tropic but also monotropic HIV-1 variants, while dextran sulfate was not effective at all against monotropic HIV-1 ( Table 2) . HIV-1 RT and integrase activities were not inhibited by the presence of DBM 2198 in an in vitro enzymatic assay (data not shown), suggesting that the anti-HIV-1 activity of DBM 2198 in cultures was not associated with the inhibition of intracellular viral specific enzymes in the infected cells. DBM 2198 exhibited little or no cytotoxicity in most cell types examined (Table 3) , minor attenuation of its anti-HIV-1 activity in the presence of serum, and was as stable as were the PAS ONs under several nuclease-containing conditions (data not shown). These results strongly suggest that DBM 2198 can be developed into a safe and effective AIDS therapeutic drug.
dG3T4G3-s, G-quartet structure PAS ON was previously reported to be effective only on T-cell-tropic HIV-1 (11) . DBM 2198, however, exhibited potent antiviral activity against a broad spectrum of HIV-1 variants, including T cell tropic (Fig.  4A ) and monotropic viruses (Fig. 4B) , as well as drug-resistant viruses (Fig. 4A, bottom 2 panels) . Interestingly, the drugresistant viruses were found to be more sensitive to DBM 2198 than were the laboratory-adapted variants (Fig. 4A) .
According to our results, SHIV 89.6 (a chimeric virus consist- Ͼ100 Ͼ100 60 Ϯ 9.4 Ͼ100 Ͼ100 Ͼ100 2180 (PϭO) 80 Ϯ 9.4 Ͼ100 Ͼ100 Ͼ100 Ͼ100 Ͼ100 2193 (4) Ͼ100 Ͼ100 67 Ϯ 14.1 Ͼ100 Ͼ100 Ͼ100 2196 (4) Ͼ100 Ͼ100 Ͼ100 Ͼ100 Ͼ100 Ͼ100 2198 (5) Ͼ100 Ͼ100 Ͼ100 80 Ϯ 9.4 Ͼ100 Ͼ100 2240 (5) Ͼ100 80 Ϯ 4.7 Ͼ100 80 Ϯ 4.7 Ͼ100 Ͼ100
a CC 50 , concentration required to inhibit cell survival 50%. Cells were incubated for 4 days in the presence of DBM ONs at different concentrations and then tested for their viability by MTT assay. Each value represents the mean cytotoxicity of triplicates, P Ͻ 0.01. ing of the SIV-originated gag-pol gene and the HIV-1-derived env gene) (28, 43, 44) was quite susceptible to the inhibitory effects of DBM 2198 (Fig. 4A and Table 2 ) while SIV was resistant to DBM 2198 (data not shown). These results imply that the anti-HIV-1 activity of DBM 2198 is reliant on the HIV-1 envelope protein, rather than on the host cell receptor. In the BLAST search for the complementary sequence of DBM 2198, no significant sequence similarity was found in the GenBank database of Eucaryota and viruses, suggesting that the sequence-specific intracellular antisense activity was not involved in the DBM 2198-mediated HIV-1 inhibition. We found that acute HIV-1 infections with high MOIs (MOI Ͼ 0.1) were not completely blocked by treatment with DBM 2198, even at a final concentration of 0.5 M (Fig. 5A) . However, we were unable to detect any syncytium formation in the DBM 2198-treated cultures, even though small amounts of HIV-1 were still detected in the supernatant by RT assay. Interestingly, the RT activity in the culture supernatant decreased with time, finally diminishing to undetectable levels (data not shown). This suggests that DBM 2198 inhibits further spread of progeny viruses by blocking the secondary infections.
In our repeated experiments, numerous syncytia in severely HIV-1-infected cultures disappeared within 2 days after treatment with DBM 2198 (Fig. 5B) . In a series of separate experiments, we found that DBM 2198 specifically blocks the HIV-1 Env protein without any interaction with the host cell membrane (data not shown). This means that the DBM 2198 blocks the Env protein on the plasma membrane of the preformed syncytia, resulting in inhibition of syncytium progression. Preformed syncytia rapidly collapsed within 2 days, probably due to intracellular HIV-1 replication, whereas preformed syncytia produced large amounts of progeny viruses, as mentioned above; however, the secondary infections of these free virus particles released from the primary infection were blocked by the presence of DBM 2198. We could not detect any recurrence of syncytia in further cultures, even though free virus particles were detected in the culture supernatant for a while in the presence of DBM 2198. The antiviral capacity of DBM 2198, as shown in the cell lines, was similarly repeated in experiments with PBMC against T-cell-tropic and monotropic HIV-1 (Fig. 6) , suggesting that DBM 2198 can be developed as a clinically applicable AIDS therapeutic agent.
In conclusion, AZN-containing PAS ONs were much more effective than pure PAS ONs for the inhibition of HIV-1 replication, without causing any cytotoxicity at concentrations of up to 100 M. DBM 2198, the most prominent for its anti-HIV-1 capacity among the AZPSONs, inhibits infection and/or replication of a broad spectrum of HIV-1 variants, including drug-resistant viruses, not only in the established cell lines but also in PBMC. Our results strongly suggest that DBM 2198 and some other effective AZPSONs can be developed into safe and effective AIDS-therapeutic drugs. The mechanisms underlying the anti-HIV-1 effects of DBM 2198 have been explored (manuscript submitted).
